Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study (Q31038347)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study (English)

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

0 references

multiple sclerosis

0 references

relapsing-remitting multiple sclerosis

1 reference

based on heuristic

inferred from title

cognitive dysfunction

1 reference

based on heuristic

inferred from title

Orietta Picconi

9

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

Mario Quarantelli

object named as

Mario Quarantelli

8

0 references

Stefano Bastianello

object named as

Stefano Bastianello

1

0 references

Maria Pia Amato

object named as

Maria Pia Amato

3

0 references

object named as

Maria Trojano

5

0 references

Giuseppe Salemi

0 references

Francesco Patti

10

object named as

Francesco Patti

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

Maria Rosaria Tola

4

object named as

Maria-Rosalia Tola

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

COGIMUS study group

11

object named as

COGIMUS study group

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

author name string

Elisabetta Giugni

2

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

Stefano Galletti

6

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

Giacomo Luccichenti

7

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

publication date

14 October 2011

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

11

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

125

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

Cortical pathology and cognitive impairment in multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214173

21 June 2018

Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing—remitting multiple sclerosis: 2-year results from the COGIMUS study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214173

21 June 2018

Cortical lesions in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214173

21 June 2018

Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214173

21 June 2018

Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214173

21 June 2018

Health-related quality of life in multiple sclerosis: effects of natalizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214173

21 June 2018

Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214173

21 June 2018

Clinical-magnetic resonance imaging correlations in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214173

21 June 2018

Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214173

21 June 2018

A rating scale for depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214173

21 June 2018

The clinico-radiological paradox in multiple sclerosis revisited

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214173

21 June 2018

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214173

21 June 2018

MRI correlates of cognitive dysfunction in multiple sclerosis patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214173

21 June 2018

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214173

21 June 2018

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-125

21 January 2018

Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-125

21 January 2018

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-125

21 January 2018

The association between cognitive impairment and quality of life in patients with early multiple sclerosis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-125

21 January 2018

Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-125

21 January 2018

The Rao's Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-125

21 January 2018

Measuring the functional impact of fatigue: initial validation of the fatigue impact scale.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-125

21 January 2018

Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-125

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-125

21 January 2018

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21999142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21999142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21999142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21999142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS

1 reference

https://pubmed.ncbi.nlm.nih.gov/21999142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

https://pubmed.ncbi.nlm.nih.gov/21999142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cognitive dysfunction in multiple sclerosis.: II. Impact on employment and social functioning

1 reference

https://pubmed.ncbi.nlm.nih.gov/21999142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuropsychological, neuroradiological and clinical findings in multiple sclerosis. A 3 year follow-up study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21999142

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2377-11-125

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1471-2377-11-125

release_urg55mim4fdlfhdkqspmlokkoa

1 reference

https://api.fatcat.wiki/v0/release/urg55mim4fdlfhdkqspmlokkoa

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31038347&oldid=2215395525"